Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Michael D. Shapiro

Fred M. Parrish Professor of Cardiology and Molecular Medicine

Wake Forest Baptist Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Biostatistics Biostatistics professors in United States

About

Michael D. Shapiro is the Fred M. Parrish Professor of Cardiology and Molecular Medicine at Wake Forest Baptist Medical Center in the United States. His research primarily focuses on cardiovascular health, including topics such as LDL-C lowering agents, familial hypercholesterolemia, and advanced lipid testing. Recent articles authored by Professor Shapiro explore the dynamics of PCSK9, the implications of statin use, and multifaceted approaches to managing prediabetes and cardiovascular risk.

Articles (10)

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Bruce Warden

Oregon Health & Science University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael D. Shapiro

Research Interests

Explore related searches

About

Articles (10)

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk

Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry

Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9

Statins and coronary artery calcium: What's the score?

Chylomicronemia syndrome: Familial or not?

A multifaceted approach for management of prediabetes and its associated cardiovascular risk

Age is just a Number (but which one is it?)

Assessing atherosclerotic cardiovascular disease risk with advanced lipid testing: State of the science

Coronary artery calcium testing in lowintermediate risk symptomatic patients with suspected coronary artery disease: An effective gatekeeper to further testing?

Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies

Collaborators (1)

Bruce Warden

Make your next move.